Arkolith/Insider Trading/AKBA/Form 4

Rucci Carolyn M.

SVP, Chief Legal OfficerAkebia Therapeutics, Inc. (AKBA) · full profile →Form 4 · filed Feb 3, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 30, 2026Grant(A)190K—$0658K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 30, 2026Grant(A)270K—$0270K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002107264-26-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML